What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- Tested for
- Severe Hypertriglyceridemia
- Main trialPhase 2
- “The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.”In the company’s words, NCT07269210 on ClinicalTrials.gov
- Other names
- LY3561774
Other drugs for Severe Hypertriglyceridemia
Coming up1
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2027 | A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | |
| Phase 2Completed | 4 Mar 2024 | A Study of LY3561774 in Participants With Mixed Dyslipidemia | |
| Phase 1Completed | 17 May 2022 | A Study of LY3561774 in Participants With Dyslipidemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026